NERLYNX + capecitabine protects against progression3
PFS IN PATIENTS WITH HER2+ mBC VS LAPATINIB + CAPECITABINE
- NERLYNX + capecitabine significantly improved median PFS vs lapatinib + capecitabine: 5.6 months with NERLYNX + capecitabine vs 5.5 months with lapatinib + capecitabine (HR=0.76; 95% CI: 0.63, 0.93; P=0.0059)3
- Median overall survival trended in favor of NERLYNX + capecitabine in patients with HER2+ mBC: 21 months with NERLYNX + capecitabine vs 18.7 months with lapatinib + capecitabine (HR=0.88; 95% CI: 0.72, 1.07; P=0.2086)3
†The total number of patients remaining in study at 24 months was 11 (9 patients receiving NERLYNX + capecitabine, 2 patients receiving lapatinib + capecitabine).
CI: confidence interval; HER: human epidermal growth factor receptor; HR: hazard ratio; mBC: metastatic breast cancer; PFS: progression-free survival.
Select IMPORTANT SAFETY INFORMATION
The most common adverse reactions (reported in ≥5% of patients) were:
- NERLYNX in combination with capecitabine: diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms.
Please see additional IMPORTANT SAFETY INFORMATION below.